한글목차

골암 치료제 시장은 2025년에는 14억 2,330만 달러로 추정되며, 2032년에는 20억 2,960만 달러에 달할 것으로 예측되며, 2025-2032년의 연평균 성장률(CAGR)은 5.2%로 성장할 것으로 예측됩니다.

암은 매우 침습적인 특성과 장기간의 투병 기간으로 인해 사망률이 높은 치명적인 만성질환 중 하나입니다. 골암은 뼈 조직이 통제할 수 없을 정도로 증식하는 암의 일종입니다. 골암 시장은 원발성 골암과 이차성 골암 등 골암의 유형에 따라 구분됩니다. 원발성 골암은 뼈와 관련 조직의 급속하고 통제할 수 없는 증식으로 인해 발생하는 암의 일종입니다. 반면 이차성 골암은 신체의 다른 부위에서 발생한 암이 뼈로 전이된 것을 말합니다. 골암은 골육종, 유잉육종, 연골육종, 척삭종, 섬유육종, 그리고 아만티노마로 분류됩니다.

시장 역학

골암에 대한 신약 출시와 규제 당국의 승인 증가는 예측 기간 중 시장 성장을 가속할 것으로 예측됩니다. 예를 들어 2020년 5월 브리스톨마이어스스퀴브(Bristol Myers Squibb)와 블루버드 바이오(bluebird bio)는 2020년 3월에 제출한 중증 전 치료 경험이 있는 재발성 난치성 다발성골수종 환자를 대상으로 한 이데카부타젠 비클루셀(이데셀, bb2121)의 생물제제 승인 신청(BLA)에 대해 미국 식품의약국(FDA)으로부터 신청 거부 통지(Refusal to File)를 받았다고 밝혔습니다. 또한 2016년 4월에는 HER2 발현 암을 표적으로 하는 Lm 기술 면역치료제 ADXS-HER2에 대해 미국 FDA로부터 외과적 절제 가능한 골육종 치료제로 Fast Tract 지정을 받았습니다. 미국 FDA의 Fast Tract 지정을 통해 회사는 개발 과정을 더욱 가속화하여 환자에게 더 빠르고 더 나은 치료를 제공할 수 있게 되었습니다.

본 조사의 주요 특징

• 이 보고서는 2024년을 기준 연도로 하여 2025-2032년의 예측 기간 중 세계 골암 치료제 시장 규모(USD Mn)와 연평균 성장률(CAGR%)을 상세하게 분석하여 전해드립니다.
• 또한 다양한 부문에 걸친 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요 인사이트을 제공합니다.
• 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등의 매개 변수를 기반으로 세계 골암 치료제 시장의 주요 기업을 프로파일링합니다.
• 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
• 세계 골암 치료제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
• 이해관계자들은 세계 골암 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.

목차

제1장 조사 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 리포트 설명
  • 시장의 정의와 범위
• 개요

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
  • 촉진요인
  • 억제요인
  • 기회
• 시장 동향
• 규제 시나리오
• 신제품 발매/승인
• 합병, 인수, 협업 시나리오
• PEST 분석
• PORTER의 산업 분석

제4장 세계의 골암 치료제 시장, 약제 유형별, 2020-2032년

• 대사 길항제
• 안트라사이클린
• 항생제
• 기타(RANK 리간드 저해제 등)

제5장 세계의 골암 치료제 시장, 적응 질환별, 2020-2032년

• 다발성골수종
• 골육종
• 연골육종
• 유잉육종

제6장 세계의 골암 치료제 시장, 유통 채널별, 2020-2032년

• 병원 약국
• 소매 약국
• 온라인 약국

제7장 세계의 골암 치료제 시장, 지역별, 2020-2032년

• 북미
  • 미국
  • 캐나다
• 유럽
  • 독일
  • 이탈리아
  • 프랑스
  • 스페인
  • 러시아
  • 기타 유럽
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • ASEAN
  • 호주
  • 한국
  • 기타 아시아태평양
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
  • 기타 라틴아메리카
• 중동
  • GCC
  • 이스라엘
  • 기타 중동
• 아프리카
  • 북아프리카
  • 중앙아프리카
  • 남아프리카공화국

제8장 경쟁 구도

• 기업 개요
  • Advaxis, Inc.
  • Cellectar Biosciences, Inc.
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Amgen Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Debiopharm Group
  • Merck &Co.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical
  • Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical

제9장 섹션

• 참고 문헌
• 조사 방법

영문목차

Bone Cancer Drugs Market is estimated to be valued at USD 1,423.3 Mn in 2025 and is expected to reach USD 2,029.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.2% from 2025 to 2032.

Cancer is one of the most prevalent fatal chronic disorders with a high mortality rate due to its extremely invasive nature and prolonged duration of disease. Bone cancer is a type of cancer in which the bone tissues grows in an uncontrollable manner. The market of bone cancer is segmented on the basis of types of bone cancer, such as, primary bone cancer and secondary bone cancer. Primary bone cancer is the type of cancer that originates from rapid and uncontrollable growth of the bone and related tissues. Whereas, Secondary bone cancer is when a cancer that started somewhere else in the body has spread to the bones. The bone cancer is also classified as, osteosarcoma, ewing's sarcoma, chondrosarcoma, chordomas, fibrosarcoma, and admantinomas.

Market Dynamics

The increasing launches of new drugs and regulatory approvals for bone cancer are expected to drive the market growth during the forecast period. For instance, in May 2020, Bristol Myers Squibb and bluebird bio announced that the companies received a Refusal to File letter from the US Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory multiple myeloma, which was submitted in March 2020. Furthermore, in April 2016, Advaxis, Inc. received the Fast Tract designation from the US FDA for ADXS-HER2, an Lm Technology immunotherapy product which target HER2 expressing cancers for the treatment of surgically-resectable osteosarcoma. The US FDA's Fast Tract designation enables the company to accelerate the development process further assisting the patients with rapid and better treatment.

Key features of the study

• This report provides in-depth analysis of the global bone cancer drug market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global bone cancer drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Advaxis, Inc., Cellectar Biosciences, Inc., OPKO Health, Inc., Pfizer Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, Debiopharm Group, Merck & Co, Bayer AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical, F. Hoffmann-La Roche Ltd, and Teva Pharmaceutical.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global bone cancer drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bone cancer drug market.

Market Segmentation

• By Drug Type Insights (Revenue, USD Mn, 2020 - 2032)
  • Antimetabolites
  • Anthracyclines
  • Antibiotics
  • Others (RANK ligand inhibitors, etc.)
• By Disease Indication Insights (Revenue, USD Mn, 2020 - 2032)
  • Multiple Myeloma
  • Osteosarcoma
  • Chondrosarcoma
  • Ewing's Sarcoma
• By Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Advaxis, Inc.
  • Cellectar Biosciences, Inc.
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Amgen Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Debiopharm Group
  • Merck & Co.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical

Table of Contents

1. Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Type
  • Market Snippet, By Disease Indication
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Market Trends
• Regulatory Scenario
• New Product Launches/Approvals
• Merger, Acquisition and Collaboration Scenario
• PEST Analysis
• PORTER's Analysis

4. Global Bone Cancer Drugs Market, By Drug Type, 2020- 2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Antimetabolites
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
• Anthracyclines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
• Antibiotics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
• Others (RANK ligand inhibitors, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020- 2032, (USD Mn)

5. Global Bone Cancer Drugs Market, By Disease Indication, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Multiple Myeloma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020- 2032, (USD Mn)
• Osteosarcoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020- 2032, (USD Mn)
• Chondrosarcoma
  • Introduction
• Ewing's Sarcoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)

6. Global Bone Cancer Drugs Market, By Distribution Channel, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020- 2032, (USD Mn)

7. Global Bone Cancer Drugs Market, By Region, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Segment Trends
• North America
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
    • U.S.
    • Canada
• Europe
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Company Profiles
  • Advaxis, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Cellectar Biosciences, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • OPKO Health, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Amgen Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Debiopharm Group
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Merck & Co.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Bayer AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Bristol-Myers Squibb Company
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Takeda Pharmaceutical
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Hoffmann-La Roche Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Teva Pharmaceutical
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Analyst Views

9. Section

• References
• Research Methodology
• About us and Sales Contact